Targeting Lipid Metabolism in Metastatic Prostate Cancer

Overview

Journal Ther Adv Med Oncol

Specialty Oncology

Date 2023 Feb 6

PMID 36743527

Authors

Tahlia Scheinberg

Blossom Mak

Lisa Butler

Luke Selth

Lisa G Horvath

Affiliations

Soon will be listed here.

Abstract

Despite key advances in the treatment of prostate cancer (PCa), a proportion of men have resistance, and all will develop resistance to current therapeutics over time. Aberrant lipid metabolism has long been associated with prostate carcinogenesis and progression, but more recently there has been an explosion of preclinical and clinical data which is informing new clinical trials. This review explores the epidemiological links between obesity and metabolic syndrome and PCa, the evidence for altered circulating lipids in PCa and their potential role as biomarkers, as well as novel therapeutic strategies for targeting lipids in men with PCa, including therapies widely used in cardiovascular disease such as statins, metformin and lifestyle modification, as well as novel targeted agents such as sphingosine kinase inhibitors, DES1 inhibitors and agents targeting FASN and beta oxidation.

Citing Articles

Unsupervised self-organising map classification of Raman spectra from prostate cell lines uncovers substratified prostate cancer disease states.

West D, Stepney S, Hancock Y Sci Rep. 2025; 15(1):773.

PMID: 39755726 PMC: 11700215. DOI: 10.1038/s41598-024-83708-6.

Evolocumab in metastatic castration-resistant prostate cancer: study protocol for a single-arm, phase II trial, and initial experience with use of a validated lipid biomarker to direct therapy.

Mellor R, Ardolino L, Scheinberg T, Fitzpatrick M, Lin H, Bonnitcha P Ther Adv Med Oncol. 2024; 16:17588359241307814.

PMID: 39691585 PMC: 11650517. DOI: 10.1177/17588359241307814.

Prostate cancer risk biomarkers from large cohort and prospective metabolomics studies: A systematic review.

Lopez-Hernandez Y, Andres-Lacueva C, Wishart D, Torres-Calzada C, Martinez-Huelamo M, Almanza-Aguilera E Transl Oncol. 2024; 51:102196.

PMID: 39580963 PMC: 11625367. DOI: 10.1016/j.tranon.2024.102196.

Nodularin-R Synergistically Enhances Abiraterone Against Castrate- Resistant Prostate Cancer via PPP1CA Inhibition.

Huang Y, Cen Y, Wu H, Zeng G, Su Z, Zhang Z J Cell Mol Med. 2024; 28(22):e70210.

PMID: 39550701 PMC: 11569623. DOI: 10.1111/jcmm.70210.

Docetaxel-Induced Cell Death Is Regulated by a Fatty Acid-Binding Protein 12-Slug-Survivin Pathway in Prostate Cancer Cells.

Liu R, Garg M, Yang X, Godbout R Int J Mol Sci. 2024; 25(17).

PMID: 39273616 PMC: 11395974. DOI: 10.3390/ijms25179669.

References

Cheung E, Pinski J, Dorff T, Groshen S, Quinn D, Reynolds C . Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial. Clin Genitourin Cancer. 2009; 7(1):43-50. DOI: 10.3816/CGC.2009.n.008. View

Zhong S, Yan X, Wu Y, Zhang X, Chen L, Tang J . Body mass index and mortality in prostate cancer patients: a dose-response meta-analysis. Prostate Cancer Prostatic Dis. 2016; 19(2):122-31. DOI: 10.1038/pcan.2015.64. View

Lin H, Yeung N, Hastings J, Croucher D, Huynh K, Meikle T . Relationship between Circulating Lipids and Cytokines in Metastatic Castration-Resistant Prostate Cancer. Cancers (Basel). 2021; 13(19). PMC: 8508038. DOI: 10.3390/cancers13194964. View

Agalliu I, Salinas C, Hansten P, Ostrander E, Stanford J . Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol. 2008; 168(3):250-60. PMC: 2585510. DOI: 10.1093/aje/kwn141. View

Weiss H, Urban D, Grizzle W, Cronin K, Freedman L, Kelloff G . Bayesian monitoring of a phase 2 chemoprevention trial in high-risk cohorts for prostate cancer. Urology. 2001; 57(4 Suppl 1):220-3. DOI: 10.1016/s0090-4295(00)00979-1. View

Jacobs E, Newton C, Thun M, Gapstur S . Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res. 2011; 71(5):1763-71. DOI: 10.1158/0008-5472.CAN-10-2953. View

Cadeddu G, Hervas-Moron A, Martin-Martin M, Pelari-Mici L, Ytuza-Charahua de Kirsch K, Hernandez-Corrales A . Metformin and statins: a possible role in high-risk prostate cancer. Rep Pract Oncol Radiother. 2020; 25(2):163-167. PMC: 6994275. DOI: 10.1016/j.rpor.2019.12.027. View

Meyer F, Bairati I, Shadmani R, Fradet Y, Moore L . Dietary fat and prostate cancer survival. Cancer Causes Control. 1999; 10(4):245-51. DOI: 10.1023/a:1008913307947. View

Alfaqih M, Allott E, Hamilton R, Freeman M, Freedland S . The current evidence on statin use and prostate cancer prevention: are we there yet?. Nat Rev Urol. 2016; 14(2):107-119. PMC: 5830185. DOI: 10.1038/nrurol.2016.199. View

10.

Gillessen S, Gilson C, James N, Adler A, Sydes M, Clarke N . Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform. Eur Urol. 2016; 70(6):906-908. DOI: 10.1016/j.eururo.2016.07.015. View

11.

Butler L, Perone Y, Dehairs J, Lupien L, de Laat V, Talebi A . Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention. Adv Drug Deliv Rev. 2020; 159:245-293. PMC: 7736102. DOI: 10.1016/j.addr.2020.07.013. View

12.

Chua C, Lee D, Ling M, Zhou C, Man K, Ho J . FTY720, a fungus metabolite, inhibits in vivo growth of androgen-independent prostate cancer. Int J Cancer. 2005; 117(6):1039-48. DOI: 10.1002/ijc.21243. View

13.

Li X, Chen Y, Hu P, Huang W . Fatostatin displays high antitumor activity in prostate cancer by blocking SREBP-regulated metabolic pathways and androgen receptor signaling. Mol Cancer Ther. 2014; 13(4):855-66. PMC: 4084917. DOI: 10.1158/1535-7163.MCT-13-0797. View

14.

Wang C, Lehman D, Lam Y, Kuhn J, Mahalingam D, Weitman S . Metformin for Reducing Racial/Ethnic Difference in Prostate Cancer Incidence for Men with Type II Diabetes. Cancer Prev Res (Phila). 2016; 9(10):779-787. PMC: 5042809. DOI: 10.1158/1940-6207.CAPR-15-0425. View

15.

Laaksonen R, Ekroos K, Sysi-Aho M, Hilvo M, Vihervaara T, Kauhanen D . Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. Eur Heart J. 2016; 37(25):1967-76. PMC: 4929378. DOI: 10.1093/eurheartj/ehw148. View

16.

Guan M, Su L, Yuan Y, Li H, Chow W . Nelfinavir and nelfinavir analogs block site-2 protease cleavage to inhibit castration-resistant prostate cancer. Sci Rep. 2015; 5:9698. PMC: 4816264. DOI: 10.1038/srep09698. View

17.

Watt M, Clark A, Selth L, Haynes V, Lister N, Rebello R . Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer. Sci Transl Med. 2019; 11(478). DOI: 10.1126/scitranslmed.aau5758. View

18.

Magliano D, Davis W, Shaw J, Bruce D, Davis T . Incidence and predictors of all-cause and site-specific cancer in type 2 diabetes: the Fremantle Diabetes Study. Eur J Endocrinol. 2012; 167(4):589-99. DOI: 10.1530/EJE-12-0053. View

19.

Mondul A, Moore S, Weinstein S, Mannisto S, Sampson J, Albanes D . 1-stearoylglycerol is associated with risk of prostate cancer: results from serum metabolomic profiling. Metabolomics. 2014; 10(5):1036-1041. PMC: 4169990. DOI: 10.1007/s11306-014-0643-0. View

20.

Bonovas S, Filioussi K, Sitaras N . Statin use and the risk of prostate cancer: A metaanalysis of 6 randomized clinical trials and 13 observational studies. Int J Cancer. 2008; 123(4):899-904. DOI: 10.1002/ijc.23550. View